164 related articles for article (PubMed ID: 32561594)
21. Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine.
Kowalewski C; Haen E; Hiemke C; Ridders F; Endres K; Gründer G; Paulzen M; Schoretsanitis G
Int Clin Psychopharmacol; 2019 Sep; 34(5):241-246. PubMed ID: 31094902
[TBL] [Abstract][Full Text] [Related]
22. CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression.
Men X; Taylor ZL; Marshe VS; Blumberger DM; Karp JF; Kennedy JL; Lenze EJ; Reynolds CF; Stefan C; Mulsant BH; Ramsey LB; Müller DJ
Clin Pharmacol Ther; 2024 May; 115(5):1065-1074. PubMed ID: 38284409
[TBL] [Abstract][Full Text] [Related]
23. Antidepressant-like effect of ethanol extract from Zuojin Pill, containing two herbal drugs of Rhizoma Coptidis and Fructus Evodiae, is explained by modulating the monoaminergic neurotransmitter system in mice.
Wang QS; Ding SL; Mao HP; Cui YL; Qi XJ
J Ethnopharmacol; 2013 Jul; 148(2):603-9. PubMed ID: 23702040
[TBL] [Abstract][Full Text] [Related]
24. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.
Lessard E; Yessine MA; Hamelin BA; Gauvin C; Labbé L; O'Hara G; LeBlanc J; Turgeon J
J Clin Psychopharmacol; 2001 Apr; 21(2):175-84. PubMed ID: 11270914
[TBL] [Abstract][Full Text] [Related]
25. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
Lessard E; Yessine MA; Hamelin BA; O'Hara G; LeBlanc J; Turgeon J
Pharmacogenetics; 1999 Aug; 9(4):435-43. PubMed ID: 10780263
[TBL] [Abstract][Full Text] [Related]
26. Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.
Kuzin M; Schoretsanitis G; Haen E; Stegmann B; Hiemke C; Gründer G; Paulzen M
Clin Pharmacokinet; 2018 Jun; 57(6):729-737. PubMed ID: 28866861
[TBL] [Abstract][Full Text] [Related]
27.
Zhou H; Yang L; Wang C; Li Z; Ouyang Z; Shan M; Gu J; Wei Y
Drug Metab Dispos; 2019 Dec; 47(12):1425-1432. PubMed ID: 31658948
[TBL] [Abstract][Full Text] [Related]
28. Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients.
Haslemo T; Eliasson E; Jukić MM; Ingelman-Sundberg M; Molden E
Br J Clin Pharmacol; 2019 Jan; 85(1):194-201. PubMed ID: 30312494
[TBL] [Abstract][Full Text] [Related]
29. Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression.
Hole K; Arnestad M; Molden E; Haslemo T
J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):281-285. PubMed ID: 33905640
[TBL] [Abstract][Full Text] [Related]
30. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
[TBL] [Abstract][Full Text] [Related]
31. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.
Fukuda T; Yamamoto I; Nishida Y; Zhou Q; Ohno M; Takada K; Azuma J
Br J Clin Pharmacol; 1999 Apr; 47(4):450-3. PubMed ID: 10233212
[TBL] [Abstract][Full Text] [Related]
32. Effect of venlafaxine dosage, valproic acid concentration, sex, and age on steady state dose-corrected concentrations of venlafaxine and O-desmethylvenlafaxine: A retrospective analysis of therapeutic drug monitoring data in a Chinese population.
Wang ZZ; Deng SH; Lu HY; Li L; Zhu XQ; Hu JQ; Xie HS; Chen HZ; Chen YQ; Zhang M; Fang ZY; Wen YG; Shang DW
Hum Psychopharmacol; 2020 May; 35(3):e2733. PubMed ID: 32239743
[TBL] [Abstract][Full Text] [Related]
33. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
Lindh JD; Annas A; Meurling L; Dahl ML; AL-Shurbaji A
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):401-6. PubMed ID: 12898080
[TBL] [Abstract][Full Text] [Related]
34. Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions.
Launiainen T; Rasanen I; Vuori E; Ojanperä I
Int J Legal Med; 2011 May; 125(3):349-58. PubMed ID: 20432045
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients.
Godoy AL; Rocha A; da Silva Souza C; Lanchote VL
J Clin Pharmacol; 2016 May; 56(5):567-75. PubMed ID: 26331791
[TBL] [Abstract][Full Text] [Related]
36. Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey.
Hefner G; Unterecker S; Shams ME; Wolf M; Falter T; Haen E; Hiemke C
J Neural Transm (Vienna); 2015 Nov; 122(11):1609-17. PubMed ID: 25940834
[TBL] [Abstract][Full Text] [Related]
37. Ethanol extract from a Chinese herbal formula, "Zuojin Pill", inhibit the expression of inflammatory mediators in lipopolysaccharide-stimulated RAW 264.7 mouse macrophages.
Wang QS; Cui YL; Dong TJ; Zhang XF; Lin KM
J Ethnopharmacol; 2012 May; 141(1):377-85. PubMed ID: 22414473
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.
Reis M; Lundmark J; Björk H; Bengtsson F
Ther Drug Monit; 2002 Aug; 24(4):545-53. PubMed ID: 12142641
[TBL] [Abstract][Full Text] [Related]
39. Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine.
Grözinger M; Dragicevic A; Hiemke C; Shams M; Müller MJ; Härtter S
Pharmacopsychiatry; 2003 Jan; 36(1):3-6. PubMed ID: 12649767
[TBL] [Abstract][Full Text] [Related]
40. PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine.
Cho CK; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
Arch Pharm Res; 2024 May; 47(5):481-504. PubMed ID: 38664354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
